ArticleIDCases2026
Emergence of dual bedaquiline and linezolid resistance during treatment of pre-extensively drug-resistant tuberculosis: A case report from Zambia.
Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-resistant tuberculosis remains a major public health threat, particularly among HIV co-infected individuals in resource-limited settings. The emergence of resistance to bedaquiline and linezolid during treatment poses a serious challenge to current therapeutic strategies. We present a case that highlights critical gaps in drug-resistant tuberculosis care. Case presentation: A 28-year-old HIV-positive Zambian man, virologically suppressed on tenofovir-lamivudine-dolutegravir, was initially treated for drug-sensitive pulmonary tuberculosis. Following relapse and treatment failure, rifampicin resistance was confirmed, and he was initiated on a second-line regimen. He was lost to follow-up and later returned with pre-extensively drug-resistant tuberculosis. A six-month regimen of bedaquiline, pretomanid, and linezolid was commenced. Despite initial improvement, persistent symptoms and hemoptysis at month five prompted resubmission of sputum for drug susceptibility testing and empirical extension of treatment; results were delayed and only became available at month 11, revealing acquired resistance to both bedaquiline and linezolid and meeting criteria for extensively drug-resistant tuberculosis. A salvage regimen comprising delamanid, ethambutol, cycloserine, clofazimine, and meropenem was initiated, and the patient remains on treatment under close clinical and laboratory monitoring. Conclusion: This case demonstrates the consequences of treatment interruption, delayed drug susceptibility testing, and inadequate monitoring in drug-resistant tuberculosis care. The simultaneous acquisition of resistance to bedaquiline and linezolid significantly limits treatment options. Strengthening adherence support, improving laboratory turnaround times, and enhancing pharmacovigilance systems are essential to preserve the effectiveness of novel regimens in Zambia and similar settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.